Five-Year LOE Impact Approaches $200bn
Stelara, Eylea, Vyvanse And Xarelto Among Key Targets For Biosimilars And Generics To 2028
As a number of major brands face generic and biosimilar competition, the loss-of-exclusivity impact across the leading 10 developed markets will approach $200bn over the next five years, according to a fresh medicines spending report running to 2028.
